Next Article in Journal
Research Evidence on High-Fat Diet-Induced Prostate Cancer Development and Progression
Next Article in Special Issue
Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks
Previous Article in Journal
Identification and Expression of Neurotrophin-6 in the Brain of Nothobranchius furzeri: One More Piece in Neurotrophin Research
Previous Article in Special Issue
Elevated Serum Interleukin-8 Level Correlates with Cancer-Related Cachexia and Sarcopenia: An Indicator for Pancreatic Cancer Outcomes
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessArticle

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma

Laboratoire d’Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, INSERM UMR1068, CNRS UMR725, F-13273 Marseille, France
Département d’Oncologie Médicale, Institut Paoli-Calmettes, F-13273 Marseille, France
Département de Chirurgie Générale et Viscérale, AP-HM, F-13000 Marseille, France
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(5), 596;
Received: 1 April 2019 / Revised: 26 April 2019 / Accepted: 28 April 2019 / Published: 30 April 2019
PDF [730 KB, uploaded 13 May 2019]
  |     |  


Pancreatic adenocarcinoma (PAC) is one of the most aggressive human cancers and new systemic therapies are urgently needed. Exportin-1 (XPO1), which is a member of the importin-β superfamily of karyopherins, is the major exporter of many tumor suppressor proteins that are involved in the progression of PAC. Promising pre-clinical data using XPO1 inhibitors have been reported in PAC, but very few data are available regarding XPO1 expression in clinical samples. Retrospectively, we analyzed XPO1 mRNA expression in 741 pancreatic samples, including 95 normal, 73 metastatic and 573 primary cancers samples, and searched for correlations with clinicopathological and molecular data, including overall survival. XPO1 expression was heterogeneous across the samples, higher in metastatic samples than in the primary tumors, and higher in primaries than in the normal samples. “XPO1-high” tumors were associated with positive pathological lymph node status and aggressive molecular subtypes. They were also associated with shorter overall survival in both uni- and multivariate analyses. Supervised analysis between the “XPO1-high” and “XPO1-low” tumors identified a robust 268-gene signature, whereby ontology analysis suggested increased XPO1 activity in the “XPO1-high” tumors. XPO1 expression refines the prognostication in PAC and higher expression exists in secondary versus primary tumors, which supports the development of XPO1 inhibitors in this so-lethal disease. View Full-Text
Keywords: pancreas cancer; prognosis; survival; XPO1 expression pancreas cancer; prognosis; survival; XPO1 expression

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Birnbaum, D.J.; Finetti, P.; Birnbaum, D.; Mamessier, E.; Bertucci, F. XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. J. Clin. Med. 2019, 8, 596.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top